PMID- 12702469
OWN - NLM
STAT- MEDLINE
DCOM- 20030618
LR  - 20141120
IS  - 0003-3898 (Print)
IS  - 0003-3898 (Linking)
VI  - 61
IP  - 2
DP  - 2003 Mar-Apr
TI  - [Matrix metalloproteinases and atherosclerosis. Therapeutic aspects].
PG  - 147-58
AB  - Matrix metalloproteinases (MMPs) play a key role in the physiology of connective 
      tissue development, morphogenesis and wound healing, but their unregulated 
      activity has been implicated in numerous disease processes including arthritis, 
      tumor cell metastasis and atherosclerosis. MMP family consists of at least 20 
      members; MMPs are produced by the different cell types (vascular smooth muscle 
      cells, monocytes, endothelial cells) involved in the atheromatous plaque 
      formation and participate to extracellular matrix remodelling and cell 
      infiltration or migration. Since excessive tissue remodelling and increased 
      matrix metalloproteinase activity have been demonstrated during atherosclerotic 
      lesion progression (including plaque disruption), MMPs represent a potential 
      target for therapeutic intervention to modify vascular pathology, by restoring 
      the MMP/TIMP physiological equilibrium. This review highlights the structures of 
      MMPs and their physiological inhibitors, the Tissue Inhibitors of MMPs (TIMPs), 
      and describes the current developments in pharmacological MMP inhibition.
FAU - Beaudeux, J-L
AU  - Beaudeux JL
AD  - Service de biochimie C, Group hospitalier Pitie-Salpetriere, AP-HP, 47-83 
      boulevard de l'hopital, 75651 Paris cedex 13. 
      jean-louis.beaudeux@psl.ap-hop-paris.fr
FAU - Giral, P
AU  - Giral P
FAU - Bruckert, E
AU  - Bruckert E
FAU - Foglietti, M-J
AU  - Foglietti MJ
FAU - Chapman, M J
AU  - Chapman MJ
LA  - fre
PT  - Comparative Study
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Metalloproteases matricielles et atherosclerose. Perspectives therapeutiques.
PL  - France
TA  - Ann Biol Clin (Paris)
JT  - Annales de biologie clinique
JID - 2984690R
RN  - 0 (Anti-Bacterial Agents)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Hydroxamic Acids)
RN  - 0 (Hypolipidemic Agents)
RN  - 0 (Matrix Metalloproteinase Inhibitors)
RN  - 0 (Organic Chemicals)
RN  - 0 (Thiophenes)
RN  - 0 (Tissue Inhibitor of Metalloproteinase-1)
RN  - 0 (Tissue Inhibitor of Metalloproteinase-3)
RN  - 0 (Tissue Inhibitor of Metalloproteinases)
RN  - 10T6626FRK (prinomastat)
RN  - 127497-59-0 (Tissue Inhibitor of Metalloproteinase-2)
RN  - 47E5O17Y3R (Phenylalanine)
RN  - BK349F52C9 (batimastat)
RN  - D5EQV23TDS (marimastat)
RN  - EC 3.4.24.- (Matrix Metalloproteinases)
RN  - EC 3.4.24.- (Metalloendopeptidases)
RN  - N12000U13O (Doxycycline)
SB  - IM
MH  - Animals
MH  - Anti-Bacterial Agents/therapeutic use
MH  - Antineoplastic Agents/therapeutic use
MH  - Aortic Diseases/blood/drug therapy/physiopathology/prevention & control
MH  - Arteriosclerosis/blood/*drug therapy/enzymology/prevention & control
MH  - Case-Control Studies
MH  - Clinical Trials as Topic
MH  - Coronary Artery Disease/drug therapy/physiopathology/prevention & control
MH  - Doxycycline/therapeutic use
MH  - Humans
MH  - Hydroxamic Acids/therapeutic use
MH  - Hyperlipidemias/complications
MH  - Hypolipidemic Agents/therapeutic use
MH  - *Matrix Metalloproteinase Inhibitors
MH  - Matrix Metalloproteinases/blood/genetics/*physiology
MH  - Metalloendopeptidases/antagonists & inhibitors
MH  - *Organic Chemicals
MH  - Phenylalanine/*analogs & derivatives/therapeutic use
MH  - Polymorphism, Genetic
MH  - Prospective Studies
MH  - Rats
MH  - Risk Factors
MH  - Thiophenes/therapeutic use
MH  - Tissue Inhibitor of Metalloproteinase-1/blood/physiology
MH  - Tissue Inhibitor of Metalloproteinase-2/physiology
MH  - Tissue Inhibitor of Metalloproteinase-3/blood/physiology
MH  - Tissue Inhibitor of Metalloproteinases/blood/metabolism/*physiology/*therapeutic 
      use
RF  - 60
EDAT- 2003/04/19 05:00
MHDA- 2003/06/19 05:00
CRDT- 2003/04/19 05:00
PHST- 2003/04/19 05:00 [pubmed]
PHST- 2003/06/19 05:00 [medline]
PHST- 2003/04/19 05:00 [entrez]
PST - ppublish
SO  - Ann Biol Clin (Paris). 2003 Mar-Apr;61(2):147-58.